Allogeneic CD56 cell-based immunotherapy in a patient with Fanconi anemia developing acute myeloid leukemia.
2/5 보강
PICO 자동 추출 (휴리스틱, conf 3/4)
유사 논문P · Population 대상 환자/모집단
환자: AML, facilitating successful HSCT
I · Intervention 중재 / 시술
CD56 cell-based immunotherapy after FLAG chemotherapy
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
[CONCLUSION] CD56 cell-based immunotherapy can effectively decrease the leukemic burden in FA patients with AML, facilitating successful HSCT. This innovative approach may enhance outcomes for high-risk patients and merits further research.
OpenAlex 토픽 ·
DNA Repair Mechanisms
Acute Myeloid Leukemia Research
Acute Lymphoblastic Leukemia research
[BACKGROUND] Fanconi anemia (FA) is a rare inherited disorder characterized by genomic instability, bone marrow failure, and a markedly increased risk of developing acute myeloid leukemia (AML).
APA
Mehdi Bakhtiyari Dovvombaygi, Amin Shahbaz Ghasabeh, et al. (2026). Allogeneic CD56 cell-based immunotherapy in a patient with Fanconi anemia developing acute myeloid leukemia.. Journal of cancer research and clinical oncology, 152(4). https://doi.org/10.1007/s00432-026-06444-6
MLA
Mehdi Bakhtiyari Dovvombaygi, et al.. "Allogeneic CD56 cell-based immunotherapy in a patient with Fanconi anemia developing acute myeloid leukemia.." Journal of cancer research and clinical oncology, vol. 152, no. 4, 2026.
PMID
41920213 ↗
Abstract 한글 요약
[BACKGROUND] Fanconi anemia (FA) is a rare inherited disorder characterized by genomic instability, bone marrow failure, and a markedly increased risk of developing acute myeloid leukemia (AML). The intrinsic hypersensitivity of FA cells to DNA-damaging agents renders conventional chemotherapy particularly toxic and often ineffective.
[CASE PRESENTATION] A 31-year-old woman with FA who progressed to AML and failed to achieve remission with standard induction therapy. Bone marrow blasts were initially 10%.
[INTERVENTION] As part of a clinical trial, she received CD56 cell-based immunotherapy after FLAG chemotherapy. She subsequently underwent allogeneic hematopoietic stem cell transplantation (HSCT) from a matched sibling donor using a CD3/CD19-depleted graft. Post-transplant, she received additional infusions of CD56 cells.
[OUTCOME] CD56 immunotherapy reduced bone marrow blasts from 10 to 3%, enabling successful HSCT. Post-transplant, she remained in complete remission with no detectable minimal residual disease (MRD) at both day +30 and day +90.
[CONCLUSION] CD56 cell-based immunotherapy can effectively decrease the leukemic burden in FA patients with AML, facilitating successful HSCT. This innovative approach may enhance outcomes for high-risk patients and merits further research.
[CASE PRESENTATION] A 31-year-old woman with FA who progressed to AML and failed to achieve remission with standard induction therapy. Bone marrow blasts were initially 10%.
[INTERVENTION] As part of a clinical trial, she received CD56 cell-based immunotherapy after FLAG chemotherapy. She subsequently underwent allogeneic hematopoietic stem cell transplantation (HSCT) from a matched sibling donor using a CD3/CD19-depleted graft. Post-transplant, she received additional infusions of CD56 cells.
[OUTCOME] CD56 immunotherapy reduced bone marrow blasts from 10 to 3%, enabling successful HSCT. Post-transplant, she remained in complete remission with no detectable minimal residual disease (MRD) at both day +30 and day +90.
[CONCLUSION] CD56 cell-based immunotherapy can effectively decrease the leukemic burden in FA patients with AML, facilitating successful HSCT. This innovative approach may enhance outcomes for high-risk patients and merits further research.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- Associations Between Sex, Disease Features and Outcome in Patients With Acute Myeloid Leukemia: A Sex-Stratified Analysis of the GIMEMA AML1310 Trial.
- Immunophenotypic Heterogeneity and Clonal Sweep in Acute Myeloid Leukemia Revealed by Flow Cytometry: A Case Series Study.
- Editorial: Exploiting biomarkers for targeted therapies in acute myeloid leukemia.
- Hyperleukocytosis and Access to Minimal Residual Disease Testing Impact Outcomes in Children With Newly Diagnosed Acute Myeloid Leukemia in Thailand.
- Leukemic appendix with clinical presentation that mimics acute appendicitis.
- Resistance to Targeted Therapy in AML: Current Challenges and Emerging Treatment Strategies.